Cargando…

Building in-house PBPK modelling tools for oral drug administration from literature information

The interest in using physiologically-based pharmacokinetic (PBPK) models as a support to the drug development decision making process has rapidly increased in the last years. These kind of models are examples of the “bottom up” modelling strategy, which progressively integrates into a mechanistic f...

Descripción completa

Detalles Bibliográficos
Autores principales: Grandoni, Silvia, Cesari, Nicola, Brogin, Giandomenico, Puccini, Paola, Magni, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Association of Physical Chemists 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957249/
https://www.ncbi.nlm.nih.gov/pubmed/35350741
http://dx.doi.org/10.5599/admet.638
_version_ 1784676727261233152
author Grandoni, Silvia
Cesari, Nicola
Brogin, Giandomenico
Puccini, Paola
Magni, Paolo
author_facet Grandoni, Silvia
Cesari, Nicola
Brogin, Giandomenico
Puccini, Paola
Magni, Paolo
author_sort Grandoni, Silvia
collection PubMed
description The interest in using physiologically-based pharmacokinetic (PBPK) models as a support to the drug development decision making process has rapidly increased in the last years. These kind of models are examples of the “bottom up” modelling strategy, which progressively integrates into a mechanistic framework different information as soon as they become available along the drug development. For this reason PBPK models can be used with different aims, from the early stages of drug development up to the clinical phases. Different software tools are nowadays available. They can be categorized in “designed software” and “open software”. The first ones typically include commercial platforms expressly designed to implement PBPK models, in which the model structure is pre-defined, assumptions are generally not explicitly declared and equations are hidden to the user. Even if the software is validated and routinely used in the pharmaceutical industry, sometimes they do not allow working with the flexibility needed to cope with specific applications/tasks. For this reason, some scientists prefer to define and implement their own PBPK tool in “open” software. This paper shows how to build an in-house PBPK tool from species-related physiological information available in the literature and a limited number of drug specific parameters generally made available by the drug development process. It also reports the results of an evaluation exercise that compares simulated plasma concentration-time profiles and related pharmacokinetic (PK) parameters (i.e., AUC, C(max) and T(max)) with literature and in-house data. This evaluation involved 25 drugs with different physico-chemical properties, intravenously or orally administrated in three different species (i.e., rat, dog and man). The comparison shows that model predictions have a good degree of accuracy, since the average fold error for all the considered PK parameters is close to 1 and only in few cases the fold error is greater than 2. In summary, the paper demonstrates that addressing specific aims when needed is possible by creation of in-house PBPK tools with satisfactory performances and it provides some suggestions how to do that.
format Online
Article
Text
id pubmed-8957249
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher International Association of Physical Chemists
record_format MEDLINE/PubMed
spelling pubmed-89572492022-03-28 Building in-house PBPK modelling tools for oral drug administration from literature information Grandoni, Silvia Cesari, Nicola Brogin, Giandomenico Puccini, Paola Magni, Paolo ADMET DMPK Original Scientific Paper The interest in using physiologically-based pharmacokinetic (PBPK) models as a support to the drug development decision making process has rapidly increased in the last years. These kind of models are examples of the “bottom up” modelling strategy, which progressively integrates into a mechanistic framework different information as soon as they become available along the drug development. For this reason PBPK models can be used with different aims, from the early stages of drug development up to the clinical phases. Different software tools are nowadays available. They can be categorized in “designed software” and “open software”. The first ones typically include commercial platforms expressly designed to implement PBPK models, in which the model structure is pre-defined, assumptions are generally not explicitly declared and equations are hidden to the user. Even if the software is validated and routinely used in the pharmaceutical industry, sometimes they do not allow working with the flexibility needed to cope with specific applications/tasks. For this reason, some scientists prefer to define and implement their own PBPK tool in “open” software. This paper shows how to build an in-house PBPK tool from species-related physiological information available in the literature and a limited number of drug specific parameters generally made available by the drug development process. It also reports the results of an evaluation exercise that compares simulated plasma concentration-time profiles and related pharmacokinetic (PK) parameters (i.e., AUC, C(max) and T(max)) with literature and in-house data. This evaluation involved 25 drugs with different physico-chemical properties, intravenously or orally administrated in three different species (i.e., rat, dog and man). The comparison shows that model predictions have a good degree of accuracy, since the average fold error for all the considered PK parameters is close to 1 and only in few cases the fold error is greater than 2. In summary, the paper demonstrates that addressing specific aims when needed is possible by creation of in-house PBPK tools with satisfactory performances and it provides some suggestions how to do that. International Association of Physical Chemists 2019-02-23 /pmc/articles/PMC8957249/ /pubmed/35350741 http://dx.doi.org/10.5599/admet.638 Text en Copyright © 2018 by the authors. https://creativecommons.org/licenses/by/3.0/This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ).
spellingShingle Original Scientific Paper
Grandoni, Silvia
Cesari, Nicola
Brogin, Giandomenico
Puccini, Paola
Magni, Paolo
Building in-house PBPK modelling tools for oral drug administration from literature information
title Building in-house PBPK modelling tools for oral drug administration from literature information
title_full Building in-house PBPK modelling tools for oral drug administration from literature information
title_fullStr Building in-house PBPK modelling tools for oral drug administration from literature information
title_full_unstemmed Building in-house PBPK modelling tools for oral drug administration from literature information
title_short Building in-house PBPK modelling tools for oral drug administration from literature information
title_sort building in-house pbpk modelling tools for oral drug administration from literature information
topic Original Scientific Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957249/
https://www.ncbi.nlm.nih.gov/pubmed/35350741
http://dx.doi.org/10.5599/admet.638
work_keys_str_mv AT grandonisilvia buildinginhousepbpkmodellingtoolsfororaldrugadministrationfromliteratureinformation
AT cesarinicola buildinginhousepbpkmodellingtoolsfororaldrugadministrationfromliteratureinformation
AT brogingiandomenico buildinginhousepbpkmodellingtoolsfororaldrugadministrationfromliteratureinformation
AT puccinipaola buildinginhousepbpkmodellingtoolsfororaldrugadministrationfromliteratureinformation
AT magnipaolo buildinginhousepbpkmodellingtoolsfororaldrugadministrationfromliteratureinformation